Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

17 June 2020

'Optimized for the underserved': A new diagnostic test built for low-income settings

In this article for Devex, Catherine Cheney reports on a new, portable diagnostic system for sickle cell disease that could serve as a model for developing testing systems for other diseases in low-resource areas.

Direct links

Read the full article

In the article, the writer examines how Gazelle, a new testing system for sickle cell disease, could impact testing systems for other health burdens including COVID-19.

Medical diagnostic device company Hemex Health is the US-based creator of Gazelle. It has programmed the diagnostic system to also test for malaria. Gazelle is specifically adapted for use in low- and middle-income countries by being affordable, fast, accurate, and easy to use.

In a discussion of Gazelle's potential application for COVID-19 diagnosis, the article quotes the Foundation's Executive Director Jayasree K. Iyer on the need for fair allocation of any resulting products.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved